UCB’s Cimzia BLA Could Provide First Subcutaneous Injection For Crohn’s
This article was originally published in Pharmaceutical Approvals Monthly
UCB is touting the "greater convenience" of its Cimzia subcutaneous injection for Crohn's disease compared to Johnson & Johnson's intravenous injection Remicade
You may also be interested in...
Ocera Therapeutics is going against the tide of biologics for Crohn’s disease as its adsorptive carbon agent AST-120 enters Phase III in fistulizing Crohn’s disease.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011